Journey Medical Corp Announces New Journey with the Experts Video Featuring Marguerite Germain, MD — Journey Medical Corporation

SCOTTSDALE, Ariz. – Nov. 18, 2022 – PRLog — Journey Medical Corporation (NASDAQ:DERM) (“Journey Medical”) today released a new Journey with the Experts video featuring Marguerite Germain, MD, a board-certified dermatologist with Germain Dermatology in Mount Pleasant, South Carolina. Dr. Germain sits down with Journey Medical to discuss confluent and reticulated papillomatosis (CARP), including what it is, why it occurs, and how those affected can seek treatment from their local dermatology practice.

According to Dr. Germain, CARP is an uncommon disorder of the skin that presents as plaques, papules, and patches that centrally coalesce and peripherally appear netlike. To view the Journey with the Experts video featuring Dr. Germain, please visit https://vimeo.com/755304356/2f8fe93aa6.

About Journey with the Experts

Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.

The information, including, without limitation, topics, presentations, discussions, content, descriptions or any other material contained herein is for informational purposes only. None of the material herein is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified HCP with any questions you may have regarding a medical condition or treatment and before undertaking a new healthcare regimen. Never disregard professional medical advice or delay seeking it because of something you have heard, observed, or inferred herein. Any reliance is strictly prohibited.

About Journey Medical Corporation

Journey Medical (NASDAQ:DERM) is a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company currently markets nine products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (NASDAQ:FBIO). For additional information about Journey Medical, visit https://journeymedicalcorp.com/.

About Marguerite Germain, MD

Dr. Germain is a board-certified dermatologist and provides exceptional service in clinical and cosmetic dermatology for patients from all over South Carolina. She graduated from Sweet Briar College in Virginia with a major in Italian studies and a minor in science, art, language, and music, and worked for the UN Food and Agricultural Organization in Italy for a year. Upon her return to the United States, Dr. Germain enrolled at the University of Maryland to continue her study of the sciences, and then attended the University of Maryland School of Medicine, receiving a Navy Medical Scholarship. For additional information about Dr. Germain, please visit https://germaindermatology.com/our-dermatologists/dr-germain-bio/.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “intend” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials, including disruptions that may result from hostilities in Europe; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees’ and consultants’ ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; potential recovery of funds lost from previously disclosed cyber security breaches; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K filed on March 28, 2022, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.